Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Telli, Melinda L. ; Hellyer, Jessica ; Audeh, William ; Jensen, Kristin C. ; Bose, Shikha ; Timms, Kirsten M. ; Gutin, Alexander ; Abkevich, Victor ; Peterson, Rebecca N. ; Neff, Chris ; Hughes, Elisha ; Sangale, Zaina ; Jones, Joshua ; Hartman, Anne-Renee ; Chang, Pei-Jen ; Vinayak, Shaveta ; Wenstrup, Richard ; Ford, James M.

Breast cancer research and treatment, 2018-04, Vol.168 (3), p.625-630 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível